86 related articles for article (PubMed ID: 17321670)
1. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Burkitt K; Ljungman M
Cancer Lett; 2007 Aug; 253(1):131-7. PubMed ID: 17321670
[TBL] [Abstract][Full Text] [Related]
2. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
Burkitt K; Ljungman M
Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
[TBL] [Abstract][Full Text] [Related]
3. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
4. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light.
Dunn J; Potter M; Rees A; Rünger TM
Cancer Res; 2006 Dec; 66(23):11140-7. PubMed ID: 17145857
[TBL] [Abstract][Full Text] [Related]
6. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
[TBL] [Abstract][Full Text] [Related]
7. Detection of impaired homologous recombination repair in NSCLC cells and tissues.
Birkelbach M; Ferraiolo N; Gheorghiu L; Pfäffle HN; Daly B; Ebright MI; Spencer C; O'Hara C; Whetstine JR; Benes CH; Sequist LV; Zou L; Dahm-Daphi J; Kachnic LA; Willers H
J Thorac Oncol; 2013 Mar; 8(3):279-86. PubMed ID: 23399959
[TBL] [Abstract][Full Text] [Related]
8. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
[TBL] [Abstract][Full Text] [Related]
9. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
Willers H; Taghian AG; Luo CM; Treszezamsky A; Sgroi DC; Powell SN
Mol Cancer Res; 2009 Aug; 7(8):1304-9. PubMed ID: 19671671
[TBL] [Abstract][Full Text] [Related]
10. Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation.
Liu Q; Ghosh P; Magpayo N; Testa M; Tang S; Gheorghiu L; Biggs P; Paganetti H; Efstathiou JA; Lu HM; Held KD; Willers H
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1081-9. PubMed ID: 25832698
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
12. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.
Kais Z; Rondinelli B; Holmes A; O'Leary C; Kozono D; D'Andrea AD; Ceccaldi R
Cell Rep; 2016 Jun; 15(11):2488-99. PubMed ID: 27264184
[TBL] [Abstract][Full Text] [Related]
13. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
[TBL] [Abstract][Full Text] [Related]
14. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
Kachnic LA; Li L; Fournier L; Ferraiolo N; Dahm-Daphi J; Borgmann K; Willers H
Cancer Lett; 2011 Jun; 305(1):86-93. PubMed ID: 21414716
[TBL] [Abstract][Full Text] [Related]
15. Generation and molecular characterization of head and neck squamous cell lines of fanconi anemia patients.
van Zeeburg HJ; Snijders PJ; Pals G; Hermsen MA; Rooimans MA; Bagby G; Soulier J; Gluckman E; Wennerberg J; Leemans CR; Joenje H; Brakenhoff RH
Cancer Res; 2005 Feb; 65(4):1271-6. PubMed ID: 15735012
[TBL] [Abstract][Full Text] [Related]
16. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer.
Park JW; Pitot HC; Strati K; Spardy N; Duensing S; Grompe M; Lambert PF
Cancer Res; 2010 Dec; 70(23):9959-68. PubMed ID: 20935219
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.
Taniguchi T; Tischkowitz M; Ameziane N; Hodgson SV; Mathew CG; Joenje H; Mok SC; D'Andrea AD
Nat Med; 2003 May; 9(5):568-74. PubMed ID: 12692539
[TBL] [Abstract][Full Text] [Related]
18. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
[TBL] [Abstract][Full Text] [Related]
19. BRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells.
Wang H; Bierie B; Li AG; Pathania S; Toomire K; Dimitrov SD; Liu B; Gelman R; Giobbie-Hurder A; Feunteun J; Polyak K; Livingston DM
Mol Cell; 2016 Jul; 63(2):277-292. PubMed ID: 27373334
[TBL] [Abstract][Full Text] [Related]
20. ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma.
Bretz AC; Gittler MP; Charles JP; Gremke N; Eckhardt I; Mernberger M; Mandic R; Thomale J; Nist A; Wanzel M; Stiewe T
Nucleic Acids Res; 2016 Apr; 44(7):3204-18. PubMed ID: 26819410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]